Page 4 - Richard Muruve News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Richard muruve. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Richard Muruve Today - Breaking & Trending Today

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , Richard Muruve , Arch Biopartners Inc , Health Canada , No Objection Letter For The Company , Turkish Ministry Of Health , Turkish Ministry , Arch Biopartners , Chief Science , Products And Services , Coronavirus Pandemic , Product Testing , Diagnosis And Treatment , Globe Newswire , International Agreements , Severe Acute Respiratory Syndrome , Lung Disease , Covid 19 Pandemic , Medical Research , Drug Trials , Clinical Trials , International Relations , North America , Infectious Diseases , Corporate News , Diseases And Conditions ,

Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of .
Arch BiopartnersFebruary 26, 2021 GMT
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Peter Lougheed Center (PLC) in Calgary, Alberta has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the prevention of acute lung injury, acute kidney injury, and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19. ....

United States , Richard Muruve , Arch Biopartners Inc , Peter Lougheed Centre , Foothills Medical Centre , Peter Lougheed Center , University Of Calgary Cumming School Medicine , Turkish Ministry Of Health , Calgary Cumming School , Turkish Ministry , Arch Biopartners , Chief Science , Products And Services , New Products And Services , Coronavirus Pandemic , Globe Newswire , Product Testing , Diagnosis And Treatment , Severe Acute Respiratory Syndrome , Lung Disease , Covid 19 Pandemic , Medical Research , Drug Trials , Clinical Trials , North America , Infectious Diseases ,

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

TORONTO, Jan. 05, 2021 Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary ....

United States , Alain Tremblay , Richard Muruve , Arch Biopartners Inc , Cumming School Of Medicine , Venture Exchange , University Of Calgary Cumming School Medicine , Regulation Services Provider , Arch Biopartners , Calgary Cumming School , Cumming School , Chief Science , Chief Executive Officer , ஒன்றுபட்டது மாநிலங்களில் , அலன் நடுக்கம் , கம்மிங் பள்ளி ஆஃப் மருந்து , துணிகர பரிமாற்றம் , பல்கலைக்கழகம் ஆஃப் கல்கரி கம்மிங் பள்ளி மருந்து , ஒழுங்குமுறை சேவைகள் வழங்குநர் , கல்கரி கம்மிங் பள்ளி , கம்மிங் பள்ளி , தலைமை அறிவியல் , தலைமை நிர்வாகி அதிகாரி ,

Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19

Share:
Government of Canada contribution up to $6.7 Million
Funding from the department of Innovation, Science and Economic Development through the Strategic Innovation Fund and part of the Government of Canada s Plan to Mobilize Science to fight COVID-19
Metablok is a novel Canadian drug candidate designed to prevent organ inflammation, which occurs in severe cases of COVID-19
TORONTO, Dec. 15, 2020 (GLOBE NEWSWIRE) Arch Biopartners Inc. ( Arch or the Company ) (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that the Government of Canada has awarded a contribution of up to $6.7 million from the department of Innovation, Science and Economic Development (ISED) to support the Phase II development of Metablok (LSALT Peptide), the Company s therapeutic drug candidate to prevent organ inflammation and injury in patients hospitalized with COVID-19. ....

United States , Richard Muruve , Navdeep Bains , Arch Biopartners Inc , Strategic Innovation Fund , Health Canada , Economic Development , Mobilize Science , Canadian Government , Arch Biopartners , Honourable Navdeep Bains , Chief Executive Officer , Chief Science , ஒன்றுபட்டது மாநிலங்களில் , நாவ்தீப் பெயின்ஸ் , மூலோபாய கண்டுபிடிப்பு நிதி , ஆரோக்கியம் கனடா , பொருளாதார வளர்ச்சி , கனடியன் அரசு , க .ரவமான நாவ்தீப் பெயின்ஸ் , தலைமை நிர்வாகி அதிகாரி , தலைமை அறிவியல் ,